Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus

Liver Transplantation Clinical Trial

— PATAC  

Official title:

A Randomized Study of Effect of Preimplantation Portal Vein and Hepatic Artery Liver Flushing With Tacrolimus on Ischemia-reperfusion Injury, Allograft Dysfunction and Liver Histology

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01887171
• Other study ID #: 1633
• Status: Completed
• Phase: N/A
• First received: April 6, 2013
• Last updated: November 3, 2014
• Start date: July 2013
• Est. completion date: July 2014

Study information

• Verified date: November 2014
• Source: Republican Scientific and Practical Center for Organ and Tissue Transplantation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belarus: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing the degree of early allograft liver dysfunction, as assessed by postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), during first 7 postoperative days and by serum and histochemical markers of liver injury and inflammation.

Description:

Early allograft liver dysfunction remains a significant complication of cadaveric liver transplantation with resource consuming and costly treatment, increased risk of multiorgan failure and 6-months mortality.

Ischemic reperfusion injury (IRI) is a main reason for early allograft liver dysfunction. Inflammatory response to brain death in donor can precipitate the extent of dysfunction after reperfusion in recipient (1). Clear inflammatory pathways in response to IRI have been reported to be associated with early allograft liver dysfunction (2,3). It was shown that ex vivo intraportal tacrolimus perfusion suppressed inflammation and immune response in the transplanted liver on a genome-wide basis (4).

We hypothesize that Tacrolimus added to HTK solution given through intraportal and intraarterial back-table infusion is capable of reducing the degree of early allograft liver dysfunction, as assessed by incidence of postreperfusion hyperfibrinolysis, postoperative levels of AST,ALT, during 1-7 postoperative days as well as serum and histochemical markers of liver injury and inflammation compared to no intraportal and intraarterial back-table infusion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Donor:

age 15-65 years macrovesicular steatosis < 40% (macroscopy or biopsy) sodium <165 mmol/l ICU stay and ventilation < 11 days cold ischemia time < 13 hours AST < 200 U/l ALT < 200 U/l bilirubin < 50 µmol/l application of norepinephrine is allowed

• Recipient age: 18-69

Exclusion Criteria:

Recipient:

• live donor liver transplant

• reduced and split grafts

• multi organ failure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Early Allograft Dysfunction
• Hyperfibrinolysis
• Ischemic Reperfusion Injury
• Liver Transplantation
• Reperfusion Injury

Intervention

Drug:
• Tacrolimus
1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4°C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.

Locations

Country	Name	City	State
Belarus	RSPC for organ and tissue transplantation, Minsk 9th clinic	Minsk

Sponsors (1)

Lead Sponsor	Collaborator
Republican Scientific and Practical Center for Organ and Tissue Transplantation

Country where clinical trial is conducted

Belarus, 

References & Publications (5)

Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003 Jul;9(7):651-63. Review. — View Citation

Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, Hancock WW, Olthoff KM. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl. 2012 Feb;18(2):166-76. doi: 10.1002/lt.22451. — View Citation

Ilmakunnas M, Tukiainen EM, Rouhiainen A, Rauvala H, Arola J, Nordin A, Mäkisalo H, Höckerstedt K, Isoniemi H. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008 Oct;14(10):1517-25. doi: 10.1002/lt.21573. — View Citation

Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T, Mühlbacher F, Oberbauer R, Bodingbauer M. Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. Transpl Int. 2011 Sep;24(9):912-9. doi: 10.1111/j.1432-2277.2011.01284.x. Epub 2011 Jun 14. — View Citation

Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010 Aug;16(8):943-9. doi: 10.1002/lt.22091. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	early allograft dysfunction	Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion.; Early allograft dysfunction will be assessed on the basis of highest levels of AST and ALT during 1-7 postoperative days.	1-7 postoperative days after liver transplant procedure	Yes
Secondary	ischemic reperfusion injury of the liver allograft	Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion.; A wedge resection of small (5x5mm) part of liver segment-III will be sampled at 2 hours after venous reperfusion. Rate of necrosis, inflammation, vascular thrombosis, cluster of differentiation (CD) 68 and High mobility group box 1 protein (HMGB1) staining will be assessed thereafter.	liver biopsy taken at 2 hours after portal reperfusion	No
Secondary	inflammatory response to reperfusion	Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion.; After unclamping portal vein but before unclamping the inferior vena cava and after venting of first 100 ml of blood a 5 ml sample of blood (code is "HV") from a tube inserted into caval suture line will be taken. Another 5 ml sample of blood (code is "C") will be taken by puncture of one of hepatic veins 20 min later. Samples (5 ml each) of peripheral blood will be taken on 1st and 3d postoperative day (POD). P-selectin, interleukin-6, interleukin-8, tumor necrosis factor alfa (TNF-a) and macrophage inflammatory protein 1 alpha (MIP-1a) will be determined in samples "HV" and "C". Interleukin-8, elastase, TNF-a and vascular endothelial growth factor (VEGF) will be determined in samples of 1st and 3d POD.	0 and 20 min after portal reperfusion, 1 and 3 postoperative day	No
Secondary	Postreperfusion hyperfibrinolysis	Protocol is restricted to liver transplants performed with classic technique with sequential portal-arterial reperfusion.; Peripheral blood samples will be taken 15 min and 2 hours after portal reperfusion.; Hyperfibrinolysis will be diagnosed by Thromboelastometry (ROTEM) if one or more following criteria are met: LI30<85% or ML>15% or LI60<85% or A10 in Extem is by 15% is less then A10 in Aptem.	15 min and 2 hours after portal reperfusion	Yes